Melvin Sanicas on Muck Rack

Melvin Sanicas

Switzerland, Zürich
As seen in: LinkedIn, Medium, El País, HuffPost, BuzzFeed, TED, MarketWatch, Agenda (World Economic Forum), China Daily (English), Les Échos and
Covers:  viruses, bacteria, infectious diseases, vaccines, innovation, digital technologies, mental health, global health
Physician-scientist (MD, MSc, MBA) #FIDSA #FRSPH #FRSA #FAcadMEd #TOYM Science & Medicine '21 #PAFIOO #PresidentialAward '24 Sharing insights on #GlobalHealth

Get in touch with Melvin

Contact Melvin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Melvin Sanicas’s Biography

Read Full Bio →

Dr. Melvin Sanicas is a physician - scientist specializing in vaccines, infectious diseases, and global health. His op-eds and articles have appeared in The World Economic Forum Agenda, Project Syndicate, HuffPost, TED Ed, Forbes, El Pais, and in over 40 print & online publications worldwide. He is a Fellow of the Royal Society of Tropical Medicine and Hygiene, a Fellow of the Royal Society for Public Health, and a Fellow of the Royal Society of Arts.

Melvin Sanicas’s Journalist Portfolio

See all 255 portfolio items →
Extremely rare case of death from bat rabies in France

Extremely rare case of death from bat rabies in France

Most bats do not have rabies. According to the US Centers for Disease Control and Prevention (CDC), even amon…

View article →
New vaccine shows protection against aerosol tuberculosis infection in monkeys

New vaccine shows protection against aerosol tuberculosis infection in monkeys

The new tuberculosis vaccine MTBVAC takes a new step as a candidate for universal vaccination against tubercu…

View article →
COVID-19 antibodies last as long as 8 months

COVID-19 antibodies last as long as 8 months

Our current understanding of SARS-CoV-2 immunity is mainly based on previous experiences with SARS-CoV (2003)…

View article →
Can aspirin reduce the risk of death in hospitalized COVID-19 patients?

Can aspirin reduce the risk of death in hospitalized COVID-19 patients?

Researchers at the University of Maryland School of Medicine showed COVID-19 patients who were taking a daily…

View article →
FDA approves first Ebola treatment

FDA approves first Ebola treatment

Over 2 years since the Kivu Ebola epidemic began in August 2018, the US Food and Drug Administration (FDA) ap…

View article →
People with blood type O may face lower risk of coronavirus infection or have milder symptoms

People with blood type O may face lower risk of coronavirus infection or have milder symptoms

Two retrospective studies in Blood Advances add evidence for an association between blood type and COVID-19 r…

View article →

Articles

Why tickborne co-infections are changing Lyme disease care

|
By Melvin Sanicas, Gjanje L. Smith, Wanneh A. Dixon
| KevinMD.com
Tickborne diseases are the most common vector-borne infections in the U.S., and for decades Lyme disease has dominated the conversation in endemic regions. But ticks are carrying more than Lyme alone and co-infections are becoming harder to ignore. New research suggests ticks are harboring a wider mix of pathogens than previously recognized, and that co-infections are becoming an increasingly important part of the clinical picture.
Open in Who Shared Issue with article?

#lithium #bipolardisorder #hiv #infection

|
By Melvin Sanicas
| LinkedIn
Researchers from McGill University report that #lithium, a long-used and inexpensive treatment for #bipolardisorder, can suppress #HIV reactivation in infected cells - an important advance in HIV cure research. ▫️ In a new study published in iScience, the team showed that lithium keeps HIV dormant in lab-grown human cells, preventing the virus from rebounding.
Open in Who Shared Issue with article?

#mpox #nigeria #sarscov2 #vaccine #immunity #smallpox

|
By Melvin Sanicas
| LinkedIn
New research shows that #mpox may be circulating silently in parts of #Nigeria, often without the classic symptoms that trigger clinical detection. The study, published in Nature Communications, was led by scientists from the University of Cambridge in collaboration with partners in Nigeria, including the Institute of Human Virology Nigeria.
Open in Who Shared Issue with article?
See all 202 articles

Interview

See all 6 answers →

Have you ever used a typewriter?

Yes. Typewriters don't need batteries, they never overheat, and your eyes won't hurt from staring too long at them.

What's your favorite social network?

Twitter, LinkedIn

Did you work for your high school newspaper? If so, what did you do there?

Yes, I was the Editor-in-Chief.

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Melvin

Contact Melvin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified